Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PCSK9 inhibitors

regeneron headquarters

UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’

CHMP has now adopted a positive opinion for the treatment

- PMLiVE

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

New approval will see Libtayo compete with blockbuster immunotherapy Keytruda

- PMLiVE

Sanofi reports a profit in Q4 as Dupixent sales climb

Shares in the French pharma company climbed around 3% in premarket activity

regeneron headquarters

EMA launches rolling review of Regeneron’s COVID-19 antibody cocktail

Study suggests REGN-COV2 can reduce viral load in non-hospitalised patients with COVID-19

- PMLiVE

Sanofi will provide manufacturing support for Pfizer/BioNTech’s COVID-19 vaccine

Sanofi is aiming to provide 100 million doses of the vaccine by the end of the year

regeneron headquarters

Regeneron’s antibody cocktail prevents COVID-19 in high-risk patients

Monoclonal antibodies prevented 100% of symptomatic infections

- PMLiVE

Amgen strikes $240m autoimmune deal with Evoq Therapeutics

Companies will collaborate on novel drugs for autoimmune disorders

Sanofi reception

Sanofi gains access to antibody tech with Kymab acquisition

French pharma will receive global rights to phase 2a monoclonal antibody

- PMLiVE

Two drugs found to reduce mortality in severe COVID-19 patients

Actemra and Kevzara also improved recovery times among critically ill COVID-19 patients

- PMLiVE

Pfizer, Sanofi and others set to increase US drug prices in 2021

Pressure from COVID-19 restrictions leads to drug price increases

- PMLiVE

Amgen aims for first KRAS inhibitor approval in the US

Sotorasib is a potential treatment for advanced KRAS G12C-mutated NSCLC

- PMLiVE

Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants

Phase 2b study has been delayed to February 2021

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links